2. Academic Validation
  3. N-Heterocyclic Carbenes as Ligands to 198Au(I)-Radiolabeled Compounds: A New Platform for Radiopharmaceutical Design

N-Heterocyclic Carbenes as Ligands to 198Au(I)-Radiolabeled Compounds: A New Platform for Radiopharmaceutical Design

  • J Med Chem. 2025 Aug 28;68(16):17516-17526. doi: 10.1021/acs.jmedchem.5c01073.
Sarah Spreckelmeyer 1,  Sophie R Thomas 2 3,  Franziska Schuderer 3 4,  Catarina I G Pinto 5,  Ana Luiza de Andrade Querino 3,  Felix A Böhm 3,  Mihyun Park 3,  Christopher Geppert 6,  Christian Gorges 6,  Filipa Mendes 5 7,  Angela Casini 3
Affiliations

Affiliations

  • 1 Department of Nuclear Medicine, Charité─Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353 Berlin, Germany.
  • 2 Department of Inorganic Chemistry, University of Vienna, Währinger Straße. 42, 1090 Vienna, Austria.
  • 3 Medicinal and Bioinorganic Chemistry, Department of Chemistry, School of Natural Sciences, Technical University of Munich, Lichtenbergstraße 4, 85748 Garching bei München, Germany.
  • 4 Pharmaceutical Radiochemistry, Department of Chemistry, School of Natural Sciences, Technical University of Munich, Walther-Meißner-Str. 3, 85748 Garching bei München, Germany.
  • 5 C2TN─Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, 2695-066 Lisboa, Portugal.
  • 6 Forschungsreaktor TRIGA Mainz, Johannes Gutenberg-Universität Mainz, Fritz-Strassmann-Weg 2, 55128 Mainz, Germany.
  • 7 DECN─Departamento de Engenharia e Ciências Nucleares, Instituto Superior Técnico, Universidade de Lisboa, 2695-066 Lisboa, Portugal.
PMID: 40797268 DOI: 10.1021/acs.jmedchem.5c01073
Abstract

The radionuclide 198Au, with a half-life of 2.7 days, emits γ radiation ideal for diagnostic purposes and generates β- particles suitable for effective Cancer radiotherapy, making it a perfect nuclide for "theranostics". However, the application of coordination compounds of Au(I)/Au(III) in medicine is limited by their instability in vivo. Here, we explore N-heterocyclic carbene (NHC) organometallic chemistry to stabilize 198Au(I) in radiopharmaceuticals. Thus, Au(I) NHC compounds featuring different scaffolds were selected for 198Au radiolabeling. Eventually, two compounds featuring imidazole (AuNHC-1) and theophylline (AuTMX2) scaffolds were successfully radiolabeled (radiochemical purity = 92.9% and 40.2%, respectively). Instead, two peptidic Au(I) benzimidazolylidene derivatives, capable of blood-brain barrier translocation in vitro, were subjected to ligand exchange reactions under the applied radiolabeling conditions. The obtained proof-of-concept results showed that NHCs are suitable ligands to achieve isotope exchange in Au(I) complexes. Overall, our work reveals the still untapped potential of organometallic chemistry in radiopharmaceutical design.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P11611
    peptide